Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Clinical trial NCT05704244 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05704244
- Sponsor
- Ferring Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-21
- Primary completion
- 2029-11-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.